Earnings Call · Q2 FY2022·2022-08-15

Q2 22EPS -17.78%·Rev n/aQ1 22EPS +9.26%·Rev n/aQ4 21EPS -33.33%·Rev n/aQ3 21EPS +6.72%·Rev n/a⚠ consensus missing

Viridian Therapeutics, Inc.\DE VRDN

John Jordan — Chief Financial Officer

Jonathan Violin — Chief Executive Officer

Barrett Katz — Chief Medical Officer

Raymond Douglas — Investigator/Clinical Expert

Kristian Humer — Chief Financial Officer

+49.4%1d on move date+48.9% vs SPY3d+54.7%5d+60.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VRDN calls or request research access.

More VRDN calls Browse calls Request research access